Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Obviously not you, Vitaros scripts are down,reverse split coming, and you double down on 290K. Stupid.
But that is why you own Apri.
Hey Carlo, straight from the 10Q,look it up yourself-
Majorelle-1st Quarter Rev-173k, 2nd Quarter Rev-160k=-13k
Bracco-1st Quarter Rev-85K, 2nd Quarter Rev-41K=-44K
Recordati-1st Quarter Rev-79K, 2nd Quarter Rev-23K=-56K
Oh yeah, must be a mistake on the 10Q.
Why doesn't Pascoe use the 200k he got in Bonus in February for the failed Fispemifine trial to buy?
Hey Carlo, did you read the last 10Q, did you see the scripts went down from the prior quarter from Majorelle by 10K, Bracco by 40k and Recordati by 60k, seems to me the product is not selling .
Why the decrease in scripts from 3 of the 4 countries launched.
Right before a 10/1-15/1 reverse split. Are you nuts.
So what will be Denner's plan, his warrants will be reduced tenfold or possibly fifteenfold with the upcoming reverse split and his exercise price will also go up that amount.
The only good thing is the same happens to Pascoe's options and the Restricted Stock Units he gave to his buddies for a job well done.
Effect of the Reverse Stock Split on Options, Warrants and Preferred Stock
The number of shares subject to our outstanding options and warrants will automatically be reduced in the same ratio as the reduction in the outstanding shares. The per share exercise price of those options and warrants will also be increased in direct proportion to the reverse stock split ratio, so that the aggregate dollar amount payable for the purchase of the shares subject to the options and warrants will remain unchanged. For example, assume that a 1-for-2 reverse stock split is implemented and that an optionee holds options to purchase 1,000 shares at an exercise price of $1.00 per share. On the effectiveness of the 1-for-2 reverse stock split, the number of shares subject to that option would be reduced to 500 shares and the exercise price would be proportionately increased to $2.00 per share. In connection with the reverse stock split, the number of shares of common stock issuable upon exercise or conversion of outstanding stock options and warrants will be rounded to the nearest whole share and no cash payment will be made in respect of such rounding. I
Absolutely None, but eicoman's post does in intrigue me, I assume he has talked to someone at apricus to get the information on the new device.
Pascoe has to have the stock more than triple and trade over a 1.00 price for ten consecutive days prior to Nov.9 to avoid a reverse split, how does he accomplish that.
No way the Nasdaq gives them an additional 180 days for the extension. Why would they, how would Pascoe convince them. They have no cash, very little revenue, no ramp up in sales for at least a year.
Seems to me , they are done.
Ferring has done just a great job, Apricus signed with them in 2015 for Latin America, over a year and no approval in Mexico and Brazil. I can't wait to see what they do now.
Remember, Nov.9 de-listing, Pascoe's options become worthless.
Carlo, did you really think Denner and Aspire were just going to sit around and not try to get back some of their money. They have kissed off their in initial investment and shorting is their only way of getting it back. Why do you think they voted Pascoe back as CEO, for his great performance, I think not. Pascoe is just a puppet for Denner and Aspire and he knows it. He is trying to milk the CEO job as long as he can because he knows he is done as a CEO for any company. Just ask yourself, would you hire him.
He has been on Holiday since he was hired.
Mean Gene, can you send me whatever you are on. First off, Rayva will not be partnered in the EU, second, Rayva phase II will not even start in the US, they don't have the money and it took 9 months to get results from the Phase 1 study with only 30 patients, third, additional launches, ha ha, they havn't had a new launch since Bracco in September of last year, that was 9 months ago, what makes you think that will change, fourth, RTD, also a laugh, it will be some minor formulation, no big deal, fifth, vitaros sales were down 40% in Q1 vs Q4, and lastly, they run out of money at the end of October. Can you spell BANKRUPTCY.
What will happen before 11/9, delisting occurs after that:
A. Pascoe resigns
B. Apri declares bankruptcy
C. Denner takes them private
D. 10-1 Reverse split
Denner had his opportunity to send a message to Pascoe and APRI.
So it is either
A. He has written off his investment and doesn't care what Pascoe and crew does, reverse split,delisting,bankruptcy or
B. He somehow intends to make money on his investment
Which is it?
Due the math people. From the latest corporate presentation ,over 1 million units sold in 2015, through the first quarter of 2016. There were 773,000 units sold through 2015 with 377,000 units sold in the fourth quarter of 2015. Lets give the them the benefit of the doubt and say 1,000,050 units sold. That equates to 227,000 units sold in the first quarter of 2016, a 40% DECREASE from the units sold in the fourth quarter of 2015.
WOW, repeat users are no longer using Vitaros. Why do you think Pascoe didn't want to hold a conference call. That would be the first question from the analysts on why such a big decrease in units sold from the fourth quarter of 2015 through the first quarter of 2016.
Hey Aprilov, please enlighten us on the "real plan" or what is going on"behind the scenes". I guess you didn't read the last 10Q report. Let me refresh you memory
It is possible that our contract manufacturers will not be able to successfully manufacture according to the requirements, and any unforeseen delay, inability
to manufacture, or any unforeseen circumstance whereby the approved product label cannot be maintained could significantly impact our financial results.
Sandoz reported that it was out-of-stock of Vitaros® in Germany in July 2015 and in Sweden and Belgium in January 2016. Sandoz has put a hold on
releasing additional batches pending the results of an ongoing out-of-specification investigation by our contract manufacturer. Such investigation relates to a
stability sample of Vitaros® manufactured for sale in the United Kingdom. All relevant health authorities have been informed and are privy to the ongoing
investigation. Our other Vitaros® partners continue to release batches and sell product in the U.K., France, Spain and Italy. There can be no assurances that we
will not experience similar manufacturing issues in the future
Sandoz has not sold product in a year. Why not?
Also, why don't you ask Matt Beck what happened to Phil Esteppa
who was in charge of the RTD. He no longer works for Apricus and they currently have no one involved with the RTD. How long will you let Pascoe pull your chain.
They were free, check out one of the last 8k's. If you were them would you risk your own money for a stock that is either going bankrupt or de-listed in 6 months.
It is possible that our contract manufacturers will not be able to successfully manufacture according to the requirements, and any unforeseen delay, inability
to manufacture, or any unforeseen circumstance whereby the approved product label cannot be maintained could significantly impact our financial results.
Sandoz reported that it was out-of-stock of Vitaros® in Germany in July 2015 and in Sweden and Belgium in January 2016. Sandoz has put a hold on
releasing additional batches pending the results of an ongoing out-of-specification investigation by our contract manufacturer. Such investigation relates to a
stability sample of Vitaros® manufactured for sale in the United Kingdom. All relevant health authorities have been informed and are privy to the ongoing
investigation. Our other Vitaros® partners continue to release batches and sell product in the U.K., France, Spain and Italy. There can be no assurances that we
will not experience similar manufacturing issues in the future
Oh by the way, Pascoe wants you to re-elect the board members and vote for a compensation package for these highly talented individuals.
May 10, 2016, Apricus Biosciences, Inc. (the “Company”) received a Nasdaq Staff Deficiency letter indicating that, for the last thirty consecutive
business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The
Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an
initial period of 180 calendar days, or until November 7, 2016, to regain compliance. The letter states that the Nasdaq staff will provide written notification
that the Company has achieved compliance with Rule 5550(a)(2) if at any time before November 7, 2016, the bid price of the Company’s common stock
closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency letter has no immediate effect on the listing or
trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “APRI.”
The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level
likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 7, 2016.
If the Company does not regain compliance with Rule 5550(a)(2) by November 7, 2016, the Company may be eligible for an additional 180
calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held
shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide
written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it
appears to the Nasdaq Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the
Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its
securities, but there can be no assurance the Staff would grant the Company’s request for continued listing.
Except for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions
reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as “believes,” “intends,” “expects,” “plans,”
and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forwardlooking.
Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such
statements. For example, there can be no assurance that the Company will meet the bid price requirement during any compliance period or otherwise in the
future, otherwise meet Nasdaq compliance standards, or that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company
can agree to or ultimately meet applicable Nasdaq requirements for any such relief. Reference is also made to other factors detailed from time to time in the
Company's periodic reports filed with the Securities and Exchange Commission, including the Company's Form 10-K and any subsequent Form 10-Q. The
forward-looking statements contained in this report speak only as of the date of this report and the Company assumes no obligation to publicly update any
forward-looking statements to reflect changes in information, events or circumstances after the date of this report, unless required by law.
* * *
2duals.
Pascoe's only hope is to sell the company within 6 months. They will be out of cash at the end of September, can't access Aspire because the stock is under 1.00,Denner is done with Pascoe, they will not be able to get and financing at all.
The million dollar question is what can he sell the company for?
.80-.90 is my guess.
Told you Pascoe wouldn't say Vitaros scripts in Q1.
You know why Pascoe is not having a call for earnings. He doesn't want to answer any questions as to why Vitaros scripts are down more than 50%. With Takeda and Sandoz not selling any scripts I bet they are less than 150,000. Who wants to bet.
Either that or he doesn't show any results of scripts written in Q1.
When will Pascoe mention the de-listing notice. Will he mention the de-listing notice in the corporate update.
Just one quick question, and DG will delete this message anyway. If things are so bright for the future, why isn't Pascoe and crew buying shares on the open market instead of giving themselves free shares. the price is a 52 week low.
hey Social, where are you.
As someone so politely said, the stock is just a bargain.
Actually, all these events are a good thing. I might even buy. Pascoe now realizes he is a two time loser. He couldn't get a CEO job of the corner newspaper stand and he knows it. His second chance of being a CEO is the company is going to be de-listed from the NASDAQ. How would you like to have that on your resume? Not me. Would any company want him to be in a management position of their company, I think not. He is taking no prisoners in trying to grow Vitaros. He should have been doing this all along.
The only extension they will get is when they request a special shareholders meeting to approve the 10-1 reverse split. Denner will be gone by then. He is already selling in big blocks. He is taking the loss and moving on. He took a shot and lost.He has already sold close to 2 mill shares.
Will Denner vote yes on a reverse split to keep listed.
How does Pascoe stop the de-listing or the reverse split??
How low can she go go go go go go go go!!!!!!!!
Don't have to worry about Apricus being taken under. Pascoe is doing just fine taking Apricus under.
How much are Pascoe's options worth.
Damage blows 6 mill, he gets canned. Pascoe blows 20 mill, get Apri into 10 mill in debt, then gets a 200k bonus. Sheez, we all should go work for them.
Wait until Pascoe shows Vitaros scripts lower in Q1 then in Q4 along with the delisting notice, Apricus will be a .30 stock.
Looks like Apricus will get a de-listing notice before the next
conference call then will either get de-listed or do a 10-1 reverse split prior to filing the NDA for Vitaros.
If a company's stock falls below $1 per share for longer than 30 days, that stock is in danger of losing its listing on the NYSE Euronext or Nasdaq exchange. Fortunately for companies, once a stock falls into the danger price zone, there is still time for the stock price to recover. A letter of notification is sent to company officials, who have another six months for the stock to strengthen to above $1 before shares are delisted from either major U.S. exchange.
Looking for a partnership?
The Company is actively seeking a global development partnership for RayVa and to out-license Vitaros® in Japan and China
Click name for e-mail
Neil Morton
Senior Vice President, Chief Business Officer
Wonder why Pascoe has not mentioned the number of Vitaros units sold in the 1st quarter
So what does that mean. Didn't Pascoe also tell Eicoman that Denner was in for the long haul on Fispemifine.
It took Pascoe ten months from when the first patient was enrolled until the results of 160 patients. How long do you think 1000 patients would take, two to three years.
You guys are better of without Fisp, they obviously didn't focus enough on Vitaros and Rayva. Now they have no choice.
So when does Denner fire Pascoe for this blunder. You can't tell me Pascoe didn't mislead him in a big way.
Hey SB, you probably don't like me much, you are spot on about Pascoe and the company.